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Abstract 41 
Objective: To analyse the association between the rs4680 Catechol-O-Methyltransferase 42 
Val158Met polymorphism and to determine the association of this polymorphism with 43 
clinical, psychological and pain sensitivity variables in women with episodic or chronic 44 
migraine. Methods: Fifty women with episodic migraine, 50 with chronic migraine, and 45 
50 matched healthy women participated. After amplifying Val158Met polymorphism by 46 
polymerase chain reaction, we assessed genotype frequencies and allele distributions. 47 
Participants were classified according to the Val158Met polymorphism genotype into 48 
Val/Val, Val/Met, or Met/Met. A headache diary was used for collecting migraine pain 49 
features. Disability was assessed with Migraine Disability Assessment Scale, trait/state 50 
anxiety levels with the State-Trait Anxiety Inventory, and depression/anxiety with the 51 
Hospital Anxiety and Depression Scale. Pressure pain thresholds (PPT) were bilaterally 52 
assessed over the temporalis, the upper trapezius, the second metacarpal and the tibialis 53 
anterior. Results: The distribution of rs4680 Val158Met genotype was not significantly 54 
different between women with/without migraine (P=0.157). No differences in migraine 55 
features were found depending on the Val158Met genotype. Women with the Met/Met 56 
genotype showed higher migraine-related disability than those with Val/Val or Val/Met 57 
genotype in both migraine groups (P<0.01). Women with chronic, but not episodic, 58 
migraine with the Met/Met genotype exhibited higher depressive and anxiety levels and 59 
lower PPTs than those with Val/Val or Val/Met genotype. Conclusion: The Val158Met 60 
rs4680 polymorphism does not appear to be involved in predisposition to suffer from 61 
migraine; however, this genetic factor may be involved in the phenotypic expression of 62 
chronic migraine, since anxiety, depression and widespread pressure pain sensitivity 63 
was greater in those women with chronic, but not episodic, migraine with the Met/Met 64 
genotype.  65 
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Catechol-O-Methyltransferase (COMT) Val158Met Polymorphism is 79 
Associated with Anxiety, Depression and Widespread Pressure Pain 80 
Sensitivity in Women with Chronic, but not Episodic, Migraine 81 
 82 
Introduction 83 
 Migraine is a primary headache disorder with a worldwide prevalence of 11.6% 84 
(13.8% females/6.9% males) (1). In the last Global Burden of Disease Study, migraine 85 
and tension-type headache were found to be the second most prevalent pain conditions 86 
in the world (2). In fact, general costs of headaches in Europe (€13.8 billion) mainly 87 
account for migraine and tension type headache (3).  88 
 It is accepted that the pathophysiology of migraine is associated with abnormal 89 
neuronal excitability leading to cortical spreading depression and to central sensitization 90 
of trigemino-vascular pathways (4). There are several factors that could affect the pain 91 
processing. One of these factors is genetics. Different genetic epidemiological studies 92 
have investigated the familial aggregation in migraine and it seems that an hereditary 93 
component can be present in some migraine types, i.e. hemiplegic migraine (5,6).  94 
The catechol-O-methyltransferase (COMT) gene is one of the potential genetic 95 
determinants in chronic pain (7). The COMT is an enzyme involved in the metabolic 96 
degradation of several neurotransmitters, e.g., dopamine, norepinephrine, or epinephrine 97 
(8). The activity of the COMT gene can be affected by different polymorphisms such as 98 
rs4680, rs6269, rs4633, or rs4818. It seems that the rs4680 genetic polymorphism due to 99 
a G→A substitution at codon 158 of this gene, leading to a valine (Val) to methionine 100 
(Met) substitution, will result in differences within COMT gene activity related to pain 101 
sensitivity. In fact, a valine (Val) allele at codon 158 results in a high-activity variant 102 
(Val/Val) whereas a methionine (Met) at this codon position (Val/Met, Met/Met) results 103 
in low-activity variants (9). It has been found that subjects with the Met/Met genotype 104 
exhibit higher pain sensitivity, that is, lower pain thresholds to different stimuli (10,11), 105 
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and different brain responses to painful stimuli (12) than those subjects with the Val/Val 106 
genotype, supporting a role of this gene in nociceptive pain processing. 107 
There are several studies investigating the role of Val158Met polymorphisms in 108 
migraine; although the results are inconsistent. The most recent meta-analysis did not 109 
observe a significant association between the Val158Met polymorphism and migraine 110 
(13). Similarly, a recent study, not included in the abovementioned meta-analysis, did 111 
not also reveal differences in Val158Met polymorphism distribution between subjects 112 
with migraine and healthy controls (14). Based on current evidence, it would seem that 113 
Val158Met polymorphism (rs4680) is not associated to a higher risk of suffering from 114 
migraine. However, it should be noted that most studies did not differentiate between 115 
episodic and chronic migraine. Similarly, another study including subjects with chronic 116 
migraine did not also find an association of the rs4680 Val158Met polymorphism with 117 
this subgroup (15).  118 
Although no differences in Val158Met polymorphism distribution would exist 119 
between individuals with and without migraine, there is evidence suggesting a genetic 120 
influence of the COMT enzyme in several aspects of different chronic pain conditions, 121 
e.g., related-fatigue and pressure pain sensitivity in breast cancer survivors (16) or mood 122 
disorders (anxiety and depression) in women with fibromyalgia (17). Therefore, it is 123 
possible that the Val158Met polymorphism can also influence some phenotypic aspects 124 
in patients with migraine. In line with this hypothesis, Park et al found that individuals 125 
with migraine carrying the Met allele experienced worse migraine-associated nausea 126 
and vomiting and higher pain intensity of migraine attacks than those with the Val allele 127 
(18). No previous study has investigated the role of the Val158Met polymorphism in 128 
clinical, psychological and pain sensitivity outcomes in women with migraine.  129 
 130 
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Therefore, the aims of the current study were: 1) to investigate the association of 131 
the Val158Met polymorphism in women with episodic or chronic migraine; and 2) to 132 
determine the relevance of the Val158Met polymorphism with clinical, psychological, 133 
and pain sensitivity variables in women with migraine.  134 
 135 
Methods 136 
Participants 137 
One hundred and twenty consecutive women with migraine were recruited from 138 
a Headache Unit located in a tertiary university-based hospital. They were diagnosed 139 
following the third edition of International Headache Society (ICHD-III) criteria down 140 
to third-digit level (code 1.1, 1.3) by an experienced neurologist (19). Migraine features 141 
including location, quality of pain, years with disease, frequency and intensity of pain 142 
attacks, family history, and medication intake were collected. To be included, subjects 143 
had to describe typical pain features of migraine pain (unilateral location, pulsating 144 
pain, high intensity, and aggravation during physical activity) and associated symptoms 145 
including photophobia, phonophobia, mild nausea or vomiting (19).  146 
         Participants were excluded if they presented any of the following: 1) other primary 147 
or secondary headache, including medication overuse headache; 2) history of cervical or 148 
head trauma; 3) pregnancy; 4) history of cervical herniated disk or cervical osteoarthritis 149 
on medical records; 5) any systemic medical disease, e.g., rheumatoid arthritis, lupus 150 
erythematous; 6) comorbid fibromyalgia syndrome; 7) had received treatment including 151 
anesthetic blocks, botulinum toxin or physical therapy within the previous 6 months; or, 152 
8) male gender. All participants were carefully interviewed for assesing their medical 153 
history. Further a medical exam, including neuro-imaging examination (MRI or CT) of 154 
the head, was performed in all patients in order to identify any exclusion criteria. 155 
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Age-matched healthy women without history of headache diagnosis and without 156 
reporting a headache pain attack during the previous year were also included. Exclusion 157 
criteria for the control group were the same as for the headache groups. All participants 158 
signed the informed consent form before their inclusion in the study. The local Ethics 159 
Committee of Hospital Rey Juan Carlos, Spain (HRJ 07/14) approved the study design. 160 
DNA Collection and COMT Genotyping 161 
          Non-stimulated whole saliva samples were collected into collection tubes (passive 162 
drooling technique) according to standardized procedures. Saliva collections were made 163 
when participants were headache-free, or with a migraine intensity of less than 3 points 164 
(in those patients with high frequency of attacks). Immediately after collection, samples 165 
were centrifuged at 3000 rpm for 15min to obtain the cell sediment and they were stored 166 
at -20º C until the analysis. We prefer to use saliva instead of blood sampling because 167 
salivary collection is a non-invasive, stress-free and ethic suitable assessment method. 168 
Laboratory technicians were blinded to the subject’s condition. Genomic DNA 169 
was hence extracted from saliva cell sediments using the “Genomic DNA extraction and 170 
purification Kit” (Real Molecular Biology) following the manufacturer instructions. The 171 
single Val158Met (rs4680) nucleotide polymorphism was genotyped using a TaqMan® 172 
Drug Metabolism Genotyping Assays on a Real Time PCR ABI Prism 7000 Sequence 173 
Detection System (APPLIED BIOSYSTEM, USA) in the Genomic Unit at the Centro 174 
de Apoyo Tecnológico Universidad Rey Juan Carlos, Madrid (Spain). The 3 possible 175 
allelic variants were associated with different fluorescent dyes to proper identification 176 
of the different genotype forms: Val/Val (H/H), Val/Met (H/L), or Met/Met (L/L). The 177 
results are derived from a G→A substitution at the following sequence:  178 
CCAGCGGATGGTGGATTTCGCTGGC [A/G] TGAAGGACAAGGTGTGCATGCCTGA 179 
 180 
 181 
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Migraine Features 182 
          A 4-weeks headache diary was used to register clinical features of migraine (20). 183 
The diary was used to calculate the following variables: 1, migraine intensity, calculated 184 
from the mean intensity of the days with s migraine attack as assessed with a 11-point 185 
numerical pain rate scale (21) (NPRS; 0: no pain, 10: maximum pain); 2, migraine 186 
frequency (days/month); and 3, migraine duration, calculated by dividing the total hours 187 
of the attack by the number of days with migraine (hours/attack). 188 
Psychological and Disability Variables 189 
The Hospital Anxiety and Depression Scale (HADS) was used to evaluate the 190 
levels of anxiety and depression. This questionnaire includes 7-items scored at a 4-191 
points scale for assessing anxiety (HADS-A) and other 7-items for assessing depressive 192 
(HADS-D) symptoms (22). Both scales are considered reliable and valid for assessing 193 
anxiety (Cronbach's α: 0.83) and depression (Cronbach's α: 0.82) (23). In subjects with 194 
headache, the HADS has shown good internal consistency (Cronbach's α: 0.84) (24).  195 
The State-Trait Anxiety Inventory (STAI) is a 40-items scale assessing separate 196 
dimensions of state anxiety (items l-20, STAI-S) and trait anxiety (items 21-40, STAI-197 
T) (25,26). The STAI-S assesses relatively enduring symptoms of anxiety at a moment, 198 
and the STAI-T scale measures a stable propensity to experience anxiety and tendencies 199 
to perceive stressful situations as threatening. Both scales have exhibited good internal 200 
consistency (a: 0.89) and high reliability (ICC: 0.88) (27). Higher scores in both scales 201 
indicate greater levels of state or trait anxiety. 202 
To assess the degree of related-disability in daily activities (work or school, 203 
family and social) caused by migraine, we used the Migraine Disability Assessment 204 
Scale (MIDAS) questionnaire. It consists of 5 questions related to days of partial or 205 
total loss within the last 3 months regarding 3 main activities: 1, paid work or school; 206 
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2, household chores; 3, family, social, or leisure activities (28). The final score comes 207 
from the sum of the missed days regarding the 3 activities. 208 
Widespread Pressure Pain Sensitivity 209 
The evaluation was held when patients were headache-free or, in those with high 210 
frequency of migraine, when the intensity of headache was less than 3 points on NPRS. 211 
Participants were asked to avoid any analgesic or muscle relaxant 24 hours prior to the 212 
examination. No change was made on the prophylactic treatment of the patients. All the 213 
participants attended a session for familiarization with the pressure test procedure over 214 
the wrist extensor muscles.  215 
Pressure pain thresholds (PPTs), i.e. the minimal amount of pressure where a 216 
sensation of pressure changes to pain (29), were assessed with an electronic algometer 217 
(Somedic AB, Farsta, Sweden). The pressure was applied perpendicularly to the point at 218 
a rate of approximately 30 kPa/s. Participants were instructed to press the “stop button” 219 
when the sensation first changed from pressure to pain. The mean of 3 trials on each 220 
point was calculated and used for the main analysis. A 30sec resting period was allowed 221 
between trials for avoiding temporal summation (30). The reliability of pressure 222 
algometry has been found to be high (31,32).  223 
         To determine widespread pressure pain sensitivity, PPTs were bilaterally assessed 224 
over a trigeminal point (i.e. temporalis muscle), an extra-trigeminal point (i.e. C5/C6 225 
joint), and two distant pain-free points (i.e. the second metacarpal and tibialis anterior 226 
muscle) by an assessor blinded to the individual’s condition. The order of assessment 227 
was randomized between participants. Since no side-to-side differences were observed, 228 
mean of both sides were used in the analysis.  229 
 230 
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Sample Size Calculation 232 
    Sample size determination and calculations were based on detecting a moderate-large 233 
effect size of 0.7 on PPTs between migraine and healthy controls related to Val158Met 234 
genotype distribution, a 2-tailed test, with an alpha level (α) of 0.05, and a desired 235 
power (β) of 90%. This generated a sample size of, at least, 42 participants per group.  236 
Statistical Analysis 237 
Data were analyzed with the SPSS statistical package (22.0 Version). Results are 238 
expressed as mean and 95% confidence interval (95% CI). The Kolmogorov-Smirnov 239 
test showed that all quantitative variables showed a normal distribution of the data (P > 240 
0.05). Comparisons of genotype distribution and allele frequency among groups were 241 
performed on raw frequencies using an extended chi-squared test (c2). A c2 analysis of 242 
the Hardy-Weinberg equilibrium for the genotypes was conducted to determine whether 243 
the allele frequencies were stable within all groups. A 2x2 analysis of variance ANOVA 244 
was used to compare clinical and psychological variables according to the Val158Met 245 
polymorphism genotype (Val/Val, Val/Met, Met/Met) in women with migraine (episodic, 246 
chronic). A 3x3 mixed-model ANOVA was used to investigate differences in PPTs over 247 
each point (temporalis, C5-C6 joint, second metacarpal, tibialis anterior) according to 248 
the Val158Met genotype (Val/Val, Val/Met, Met/Met) and group (episodic migraine, 249 
chronic migraine, healthy control). Post-hoc analyses comparisons were conducted with 250 
the Bonferroni test. The statistical analysis was conducted at a 95% confidence level. A 251 
P value less than 0.05 was considered statistically significant. 252 
 253 
 254 
 255 
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Results 256 
One hundred and twenty (n=120) consecutive women presenting with headache 257 
were screened for eligibility criteria. Twenty (17%) were excluded for the following 258 
reasons: co-morbid headaches (n=7); previous head or neck trauma (n=6); receiving 259 
anaesthetic block in the past 3 months (n=5) or pregnancy (n=2). Finally, 50 women 260 
with chronic migraine (age: 43±12 years), 50 with episodic migraine (age: 42±13 years) 261 
satisfied all criteria, signed the informed consent, and agreed to participate. Further, 50 262 
age-matched women without headache (age: 43±11 years) were also included. Table 1 263 
summarizes clinical, psychological and pain sensitivity data of the sample. Women with 264 
chronic migraine exhibited significant higher headache frequency (P<0.001) and higher 265 
migraine-related disability (P=0.04) than those with episodic migraine. Further, women 266 
with episodic or chronic migraine exhibited higher widespread pressure pain sensitivity 267 
(P<0.001) than healthy women, without differences between them (P>0.9). 268 
Distribution of Val158Met Polymorphism in migraine 269 
The genotype distributions in women with and without migraine did not deviate 270 
from those expected based on the Hardy-Weinberg equilibrium. The distribution of the 271 
Val158Met genotypes (c2=6.63; P=0.157) was not significantly different among women 272 
with episodic or chronic migraine and healthy women (table 2).  273 
Clinical and psychological measures and Val158Met Polymorphism  274 
 The mixed-model ANOVA did not reveal significant differences depending on 275 
the Val158Met polymorphism genotype (table 3) in both groups of migraine women for 276 
years with pain (F=0.874; P=0.420), migraine intensity (F=0.172; P=0.842), migraine 277 
frequency (F=1.986; P=0.143), and migraine duration (F=0.308; P=0.736).  278 
 279 
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Similarly, no significant differences depending on the Val158Met polymorphism 280 
genotype were either found (table 4) in both women with episodic or chronic migraine 281 
for STAI-T (F=0.340; P=0.712), and HADS-A (F=1.494; P=0.188). A significant group 282 
* Val158Met genotype interaction was observed for HADS-D (F=4.369; P=0.015) and 283 
STAT-S (F=3.219; P=0.045): women with chronic migraine, but not those with episodic 284 
migraine, carrying the Met/Met genotype showed higher depressive and anxiety state 285 
levels than those carrying the Val/Val (P=0.01) or Val/Met (P=0.04) genotype. Finally, 286 
significant differences based on the Val158Met polymorphism genotype for the MIDAS 287 
(F=7.078 P<0.001) were found in both migraine groups: women carrying the Met/Met 288 
genotype exhibited higher levels of related-disability than those with the Val/Val or the 289 
Val/Met genotype (P<0.01) in both episodic and chronic migraine groups (table 4). 290 
Pressure pain sensitivity and Val158Met polymorphism  291 
 All patients with episodic migraine and 45 (90%) patients with chronic migraine 292 
were headache-free during PPT examination. The 3x3 mixed-model ANOVA revealed 293 
significant group*Val158Met polymorphism genotype interactions for PPTs over the 294 
temporalis muscle (F=3.714; P=0.025), the second metacarpal (F=3.641; P=0.024), and 295 
tibialis anterior (F=3.431; P=0.03), but not for the C5-C6 zygapophyseal joint (F=1.479; 296 
P=0.212). Women with chronic migraine with the Met/Met genotype showed lower PPT 297 
than women with chronic migraine with the Val/Met or Val/Val genotype (P<0.001). 298 
No significant differences existed in PPTs between women with chronic migraine with 299 
the Val/Val or Val/Met genotypes (P>0.5). Table 5 shows PPT according to Val158Met 300 
polymorphism in women with episodic and chronic migraine and healthy women.  301 
 302 
 303 
 304 
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Discussion 305 
The current study found no differences in the genotype distribution and allele 306 
frequency of the Val158Met polymorphism between those women with migraine, either 307 
episodic or chronic, and healthy women. Further, the presence of the Met/Met genotype 308 
was associated to higher levels of anxiety, depression, disability and greater widespread 309 
pressure hyperalgesia, in women with the chronic, but not episodic, form of the disease.  310 
Val158Met polymorphism and migraine 311 
We did not observe significant differences in the distribution of the Val158Met 312 
polymorphism between women with episodic or chronic migraine and healthy women, 313 
supporting the assumption that this polymorphism is not involved in a predisposition to 314 
suffer from migraine. Our results agree with a recent systematic review concluding that 315 
the Val158Met polymorphism was not associated with migraine risk (13). Additionally, 316 
Takigawa et al did not also observe differences in the presence of other haplotypes of 317 
the COMT gene, e.g., rs4633, rs6267, rs6270 between individuals with migraine and 318 
healthy people (14). Nevertheless, since the rs4680 Val158Met polymorphism has been 319 
associated, in some studies, to different conditions, e.g., fibromyalgia syndrome (33) or 320 
temporomandibular pain (34), it is possible that it could be associated to some particular 321 
pain conditions rather than to chronic pain in general. Furthermore, since migraine is 322 
comorbid with other chronic pain syndromes, i.e. fibromyalgia (35), we do not know if 323 
different subgroups of patients with migraine and co-morbid conditions would lead to 324 
different associations. Obviously, the fact that the rs4680 Val158Met polymorphism is 325 
not associated with migraine does not exclude the role of genetics in this headache 326 
form. Therefore, future studies investigating the role of other genetic components in 327 
migraine are guaranteed. 328 
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It has been previously that the Val158Met can be associated with worse clinical 329 
presentation of migraine. For instance, individuals with migraine carrying the Met allele 330 
experienced higher pain intensity and worse migraine-associated symptoms than those 331 
with Val allele (18). We observed that women with migraine, either episodic or chronic, 332 
with the Met/Met genotype exhibited higher migraine-related disability as assessed with 333 
the MIDAS than those with Val/Met or Val/Val genotype. Further, a Met/Met genotype 334 
was also associated with higher depressive and anxiety state levels, but only within the 335 
chronic migraine group, suggesting that the Val158Met polymorphism can play a role in 336 
different psychological aspects. In fact, our results agree with previous studies showing 337 
that the Met allele is associated with anxiety-related behaviors in healthy women (36), 338 
with higher stress responses after a whiplash injury (37), or with higher psychological 339 
distress in fibromyalgia syndrome (38). A potential explanation for these findings could 340 
be related to the fact that individuals carrying the Met/Met genotype had greater brain 341 
activation of the limbic region as response to emotionally challenging situations (39,40). 342 
Additionally, Met/Met carriers exhibited lower activation of the dorso-lateral pre-frontal 343 
cortex and cingulate cortex than Val/Val carriers (41). Therefore, it is also possible that 344 
individuals with the Met/Met genotype exhibit different cortical activation patterns than 345 
those carrying the Val/Val genotype.  346 
Val158Met polymorphism and pain hyperexcitability 347 
Another relevant finding of the current study is that women with chronic, but not 348 
episodic, migraine carrying the Met/Met genotype exhibited higher widespread pressure 349 
pain sensitivity than those with the Val/Val or Val/Met genotype. These findings would 350 
suggest that the Val158Met polymorphism could play a role within the nociceptive pain 351 
processing in the chronic form of the disease. A potential association of the Val158Met 352 
polymorphism with higher sensitivity to pressure pain has been previously observed in 353 
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children with chronic tension type headache (42) and women with fibromyalgia (43). 354 
Our study is the first reporting an association between the Val158Met polymorphism 355 
and widespread pressure pain sensitivity in chronic migraine. Several mechanisms could 356 
explain this association. For instance, a reduction within COMT gene activity associated 357 
with the Met allele at codon 158 of the Val158Met leads to a reduction in the content of 358 
enkephalins in some regions of the central nervous system associated with pain (9). This 359 
hypothesis would correlate with the presence of hyper-excitability of the central nervous 360 
system and of endogenous inhibitory pain pathways previously observed in adults with 361 
chronic migraine (44). In fact, migraine has been associated with a non-physiological 362 
production of some neuromodulators (45). Therefore, another potential mechanism may 363 
be an increase of catecholamine levels, which will promote stimulation of b2-adrenergic 364 
receptors in the central nervous system, associated with a reduced COMT gene activity 365 
(46). Since individuals with migraine exhibit hyper-excitability of the central nervous 366 
system, it is possible that the presence of the Met/Met genotype, in some predisposed 367 
subjects, could contribute to this process. In fact, this hypothesis is also suggested in 368 
subjects with fibromyalgia (47).  369 
Limitations 370 
Although the results of this study are informative, potential limitations should be 371 
considered. First, we included women with migraine and derived from a specialized 372 
tertiary hospital center. Therefore, our results should be not extrapolated to men and to 373 
other primary headaches such as tension-type headache. Second, it is possible that the 374 
study was underpowered for other outcomes different than PPTs. Therefore, a greater 375 
sample size including patients from the general population would be needed to further 376 
confirm these results. Third, we only investigated the rs4680 nucleotide of Val158Met 377 
polymorphism. Future studies should include a greater number of polymorphisms and 378 
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other genes to further clarify their potential role in the phenotypic expression of chronic 379 
migraine. 380 
 381 
Conclusions 382 
No differences were found in the genotype distribution and allele frequency of 383 
the Val158Met polymorphism between women with migraine, either episodic or chronic 384 
and healthy women. The presence of the Met/Met genotype was associated with higher 385 
related-disability in both episodic and chronic migraine, and with higher depressive and 386 
anxiety levels, and higher pressure pain hyperalgesia but only in the chronic migraine 387 
group. Our results suggest that the rs4680 Val158Met polymorphism may contribute to 388 
the altered nociceptive pain processing in women with chronic migraine and may 389 
contribute to the chronification process. 390 
 391 
 392 
 393 
 394 
 395 
 396 
 397 
 398 
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 400 
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